EDAP TMS SA Announces Strong Financial Results for Full-Year 2024 and Recent Achievements in HIFU Technology
EDAP TMS SA, a leading global company in robotic energy-based therapies, recently reported its unaudited consolidated financial results for the fourth quarter and full-year 2024. The company showcased impressive revenue growth and significant advancements in its HIFU (High Intensity Focused Ultrasound) technology.
Financial Highlights
EDAP TMS SA reported a full-year 2024 HIFU revenue of USD 25.7 million, representing an increase of 15.3% compared to full-year 2023. The company’s robust performance continued in the fourth quarter, with HIFU revenue reaching USD 9.3 million, marking a 15.0% increase over Q4 2023.
Growth in Focal One Procedures
The strong financial performance was driven by a 51% year-over-year increase in U.S. Focal One HIFU procedures in 2024. This growth demonstrates the growing demand for this advanced treatment and the confidence of healthcare professionals in the technology.
Regulatory Approvals and Clinical Studies
EDAP TMS SA also announced that the Focal One system received the CE Mark for the treatment of deep infiltrating endometriosis. Furthermore, a recent landmark HIFI study publication demonstrated positive outcomes with Focal One Robotic HIFU versus surgery in the management of prostate cancer. These achievements further solidify the company’s position as a leader in the field.
New Applications for Focal One Technology
Additionally, the first patients have been treated in a Phase I/II study evaluating Focal One Robotic HIFU for the treatment of Benign Prostatic Hyperplasia (BPH). This expansion into new indications highlights the versatility and potential of the Focal One technology.
Impact on Individuals and the World
For individuals, the advancements in HIFU technology, such as the Focal One system, offer more precise and effective treatments for various conditions, including prostate cancer and endometriosis. These minimally invasive procedures can lead to shorter recovery times, fewer side effects, and improved quality of life.
On a global scale, the continued growth and success of EDAP TMS SA in the HIFU market can lead to increased access to advanced treatments for a wider population, potentially reducing the burden on healthcare systems and improving overall patient outcomes.
Conclusion
EDAP TMS SA’s strong financial results for full-year 2024 and recent achievements in HIFU technology, including regulatory approvals, clinical studies, and new applications, underscore the company’s position as a global leader in robotic energy-based therapies. These advancements offer hope for individuals seeking more precise and effective treatments for various conditions, while also contributing to the overall improvement of healthcare systems and patient outcomes.
- EDAP TMS SA reported impressive financial results for full-year 2024, with a 15.3% increase in HIFU revenue compared to full-year 2023
- Q4 2024 HIFU revenue increased by 15.0% over Q4 2023
- U.S. Focal One HIFU procedures grew by 51% year-over-year in 2024
- Focal One received CE Mark for the treatment of deep infiltrating endometriosis
- Positive outcomes with Focal One Robotic HIFU versus surgery in the management of prostate cancer were published in a recent study
- First patients were treated in a Phase I/II study evaluating Focal One Robotic HIFU for the treatment of BPH
- Advancements in HIFU technology offer more precise and effective treatments with shorter recovery times and fewer side effects for individuals
- Continued growth and success of EDAP TMS SA in the HIFU market can lead to increased access to advanced treatments and improved healthcare systems and patient outcomes globally
